Understand the source comparison
SS-LUP-332 vs Other Endurance Research Tools: What Each Isolates
SS-LUP-332 ERRα receptor agonist Yes. 30–40% increase in 4 weeks Yes. Resting and low-intensity Modest improvement (+10–15%) Limited. Oxidative capacity only Best for isolating ERRα-dependent mitochondrial outcomes; does not replicate full training adaptation
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SS-LUP-332
- ERRα receptor agonist
- Yes. 30–40% increase in 4 weeks
- Yes. Resting and low-intensity
- Modest improvement (+10–15%)
- Limited. Oxidative capacity only
- Best for isolating ERRα-dependent mitochondrial outcomes; does not replicate full training adaptation
- AICAR (AMPK activator)
- AMPK pathway activation
- Moderate. 15–20% increase
- Yes. Via CPT1 upregulation
- Moderate improvement (+15–20%)
- Moderate. Includes some glycolytic signaling
- Broader metabolic signal than SS-LUP-332; useful for AMPK-specific questions but less mitochondrial specificity
- GW501516 (PPARδ agonist)
- PPARδ transcription
- Yes. 25–35% increase
- Strong. Preferential fat oxidation
- Significant improvement (+25–30%)
- High. Near-training equivalent
- Most comprehensive pharmacological mimic of endurance training; regulatory concerns limit use
- Endurance Training (8–12 weeks)
- Multi-pathway (AMPK, Ca2+, ROS, ERRα)
- Yes. 35–50% increase
- Yes. Metabolic flexibility develops
- Significant improvement (+30–40%)
- High. Full adaptation
- Gold standard but cannot isolate individual pathways; confounded by systemic variables